Abonour, Rafat

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 933

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

The Cancer Loneliness Scale and Cancer-related Negative Social Expectations Scale: development and validation

Adams, R. N., Mosher, C. E., Rand, K. L., Hirsh, A. T., Monahan, P. O., Abonour, R., & Kroenke, K. (2017) · Quality of Life Research

Cancer survivorship and careHealth disparities and outcomes

Cited by 49

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Popat, R., Nooka, A., Stockerl-Goldstein, K., Abonour, R., Ramaekers, R., Khot, A., Forbes, A., Lee, C., Augustson, B., Spencer, A., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 47

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 13

Phase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Tiu, R. V., Wang, X., Callies, S., Cox, J., Tuttle, J. L., et al. (2015) · Blood

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 6

P-285 Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connectmultiple myeloma disease registry

Lee, H., Ailawadhi, S., Dhanda, D., Patwardhan, P., Yu, E., Liu, L., Rifkin, R., Terebelo, H., Abonour, R., Narang, M., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1